Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingJuliann Chmielecki, William Pao, Nicholas D. Socci et al.|Science Translational Medicine|2011Cited by 530
Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast CancerNicholas C. Turner, Komal Jhaveri, Seock‐Ah Im et al.|New England Journal of Medicine|2024Cited by 235
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Giles Robinson et al.|Neuro-Oncology|2022Cited by 136
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epitheliumJustin M. Balko, Rebecca S. Cook, Todd W. Miller et al.|Proceedings of the National Academy of Sciences|2011Cited by 75
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.Giles Robinson, Ami V. Desai, Amar Gajjar et al.|Journal of Clinical Oncology|2019Cited by 61